江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2014年
9期
785-788
,共4页
王凌玲%雷梦觉%周桂秀%胡杰%龚爱斌%魏伟荣
王凌玲%雷夢覺%週桂秀%鬍傑%龔愛斌%魏偉榮
왕릉령%뢰몽각%주계수%호걸%공애빈%위위영
钙调神经磷酸酶%正常高值血压%左室肥厚%内皮素-1
鈣調神經燐痠酶%正常高值血壓%左室肥厚%內皮素-1
개조신경린산매%정상고치혈압%좌실비후%내피소-1
Calcineurin%Perhypertension%Left ventricular hypertrophy%Endothelin-1
目的探讨血清钙调神经磷酸酶(CaN)在正常高值血压患者左室肥厚中的表达。方法共选取健康体检人群282例,根据血压分为正常血压组(n=78),正常高值血压组(n=122),高血压组(n=82);再将正常高值血压组根据左室质量指数(LVMI)和相对室壁厚度(RWT)值分为正常构型亚组(n=101)、左室肥厚亚组(n=21)。采用超声心动图测定计算LVMI、RWT,酶联免疫法测定血清CaN水平,比色法测定血清CaN活性,放射免疫法测定血清内皮素-1(ET-1),分析其与正常高值血压左室肥厚的关系。结果⑴在正常血压组、正常高值血压组、高血压组中,左室肥厚发生率分别为7.82%、17.21%、22.35%;LVMI、RWT、血清CaN活性、ET-1水平依次升高,差异具有显著性(P<0.05)。正常高值血压组、正常血压组两组之间的差异(P<0.05),比高血压组、正常高值血压组两组之间的差异(P<0.01)更具有显著性。⑵正常高值血压组中左室肥厚亚组血清CaN活性、ET-1均高于正常构型亚组(P<0.05)。结论正常高值血压左室肥厚发生率、CaN活性明显高于正常血压。活化的CaN促进了正常高值血压左室肥厚的发生发展。
目的探討血清鈣調神經燐痠酶(CaN)在正常高值血壓患者左室肥厚中的錶達。方法共選取健康體檢人群282例,根據血壓分為正常血壓組(n=78),正常高值血壓組(n=122),高血壓組(n=82);再將正常高值血壓組根據左室質量指數(LVMI)和相對室壁厚度(RWT)值分為正常構型亞組(n=101)、左室肥厚亞組(n=21)。採用超聲心動圖測定計算LVMI、RWT,酶聯免疫法測定血清CaN水平,比色法測定血清CaN活性,放射免疫法測定血清內皮素-1(ET-1),分析其與正常高值血壓左室肥厚的關繫。結果⑴在正常血壓組、正常高值血壓組、高血壓組中,左室肥厚髮生率分彆為7.82%、17.21%、22.35%;LVMI、RWT、血清CaN活性、ET-1水平依次升高,差異具有顯著性(P<0.05)。正常高值血壓組、正常血壓組兩組之間的差異(P<0.05),比高血壓組、正常高值血壓組兩組之間的差異(P<0.01)更具有顯著性。⑵正常高值血壓組中左室肥厚亞組血清CaN活性、ET-1均高于正常構型亞組(P<0.05)。結論正常高值血壓左室肥厚髮生率、CaN活性明顯高于正常血壓。活化的CaN促進瞭正常高值血壓左室肥厚的髮生髮展。
목적탐토혈청개조신경린산매(CaN)재정상고치혈압환자좌실비후중적표체。방법공선취건강체검인군282례,근거혈압분위정상혈압조(n=78),정상고치혈압조(n=122),고혈압조(n=82);재장정상고치혈압조근거좌실질량지수(LVMI)화상대실벽후도(RWT)치분위정상구형아조(n=101)、좌실비후아조(n=21)。채용초성심동도측정계산LVMI、RWT,매련면역법측정혈청CaN수평,비색법측정혈청CaN활성,방사면역법측정혈청내피소-1(ET-1),분석기여정상고치혈압좌실비후적관계。결과⑴재정상혈압조、정상고치혈압조、고혈압조중,좌실비후발생솔분별위7.82%、17.21%、22.35%;LVMI、RWT、혈청CaN활성、ET-1수평의차승고,차이구유현저성(P<0.05)。정상고치혈압조、정상혈압조량조지간적차이(P<0.05),비고혈압조、정상고치혈압조량조지간적차이(P<0.01)경구유현저성。⑵정상고치혈압조중좌실비후아조혈청CaN활성、ET-1균고우정상구형아조(P<0.05)。결론정상고치혈압좌실비후발생솔、CaN활성명현고우정상혈압。활화적CaN촉진료정상고치혈압좌실비후적발생발전。
Objective To investigate the role of the serum calcineurin (CaN)in perhypertension left ventricular hypertrophy. Methods From February 2011 to January 2014,282 healthy crowd were selected from The Jiangxi province People's Hospictal. Based on the blood pressure,all of them were divided into three groups:the normal blood pressure group (n=78),the perhyperten-sion group (n=122) and the hypertension group (n=82). Based on the left ventricular mass index (LVMI)and the relative ventricular wall thickness(RWT),the perhypertension group were divided into two groups:the normal model subgroup(n=101) and the left ven-tricular hypertrophy subgroup (n=21). LVMI,RWT were determined by echocardiography;serum calcineurin levels were measured by the Enzyme-linked immunosorbent assay method;serum calcineurin enzymatic activities were measured by the colorimetric and serum Endothelin-1(ET-1)levels were measured by the radioimmunoassay method. The role of the serum CaN,ET-1 in perhyper-tension left ventricular hypertrophy was analyzed. Results ⑴In the normal blood pressure group,perhypertension group,hyperten-sion group the incidence of the left ventricular hypertrophy were 7.82%,17.21%,22.35%respectively;the LVMI,RWT,serum CaN activity and serum ET-1 levels increased successively. There were significant differences (P<0.05). The differences between the normal blood pressure group and the perhypertension group(P<0.05)were more significant than the differences between the perhy-pertension group and the hypertension group(P<0.01).⑵In the perhypertension group,the serum CaN activity、serum ET-1 levels in the Left ventricular hypertrophy subgroup were higher than the normal model subgroup (P<0.05). Conclusion The incidence and serum CaN activity of the left ventricular hypertrophy in the perhypertension group were higher than that of the normal blood pressure group. The CaN activated advanced the occurrence and development of the left ventricular hypertrophy in the perhyper-tension.